Európai Unió - litván - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - macimorelin acetatas - diagnostikos metodus, endokrininės sistemos - macimorelin - Šis vaistas yra skirtas tik diagnostikai.  ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.

Európai Unió - litván - EMA (European Medicines Agency)

qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - Šunys - gydyti ne resectable, ne metastazavusio (kurie sustojimo) poodinio putliųjų ląstelių navikai įsikūręs, ar distalinės į alkūnės arba kulno, ir ne resectable, neišplitusia odos putliųjų ląstelių navikų šunys.

Európai Unió - litván - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - limfoma, b-ląstelių - antinavikiniai vaistai - polivy kartu su bendamustine ir rituximab fluorouracilu ir folino suaugusių pacientų su atsinaujino/ugniai atsparūs difuzinė didelių b ląstelių limfoma (dlbcl), kurie nėra kandidatų kraujodaros kamieninių ląstelių transplantacijos. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Európai Unió - litván - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - virškinimo trakto stromos navikai - kiti antinavikiniai vaistai agentai, baltymų kinazės inhibitoriai - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Európai Unió - litván - EMA (European Medicines Agency)

insmed netherlands b.v. - amikacin sulfate - kvėpavimo takų infekcijos - antibacterials sisteminio naudojimo, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.

Európai Unió - litván - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Európai Unió - litván - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - kiti nervų sistemos vaistai - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Európai Unió - litván - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - kiaulės - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Európai Unió - litván - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - raumenų atrofija, nugaros smegenys - kiti vaistai nuo raumenų ir skeleto sistemos sutrikimų - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.

Európai Unió - litván - EMA (European Medicines Agency)

mylan ireland limited - abiraterono acetatas - prostatos navikai - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.